Tilray’s (TLRY) domestic business is showing signs the struggle continues in an oversupplied Canadian cannabis market where prices have taken a tumble. However, the most positive aspect in the company’s recent quarterly report, according to Cantor analyst Pablo Zuanic, is the “continued strength in the international business.” In F3Q22, the company generated revenue of $151.87 million, amounting to a 22.6% year-over-year increase, although the figure fell short of the $156.2 million the analysts were expecting. In a market which saw a 5% downturn, recreational sales dropped by 12% quarter-over-quarter and medical declined by 11%.
https://www.tipranks.com/news/article/tilray-stock-increasing-profitability-but-still-not-a-buy?utm_source=advfn.com&utm_medium=referral